Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Trevi Therapeutics clinical trials
The registry lists 17 studies whose lead sponsor is Trevi Therapeutics. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 13, 2026.
Keep track of what changes. Save the Trevi Therapeutics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Trevi Therapeutics.
- Trevi Therapeutics17 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 17 of 17.
- The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)RecruitingNCT07671924Phase 2
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsRecruitingNCT07671911Phase 3
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) TabletsRecruitingNCT07868419Phase 3
- A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy ParticipantsCompletedNCT07487740Phase 1
- NAL ER IPF Respiratory Function and Safety StudyCompletedNCT07036029Phase 1
- Cough Reduction in IPF With Nalbuphine ERCompletedNCT05964335Phase 2
- Refractory Chronic Cough Improvement Via NAL ER (RIVER)CompletedNCT05962151Phase 2
- Study of Nalbuphine ER in Participants With Hepatic ImpairmentCompletedNCT04020016Phase 1
- A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy ParticipantsCompletedNCT07015398Phase 1
- PRISM Study-Pruritus Relief Through Itch Scratch ModulationCompletedNCT03497975Phase 2/3
- A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughCompletedNCT04030026Phase 2
- Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic PruritusCompletedNCT02373215Phase 1
- Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic PruritusCompletedNCT02143973Phase 2/3
- Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic PruritusCompletedNCT02143648Phase 2/3
- Study of Nalbuphine HCl ER Tablets in Patients With Prurigo NodularisCompletedNCT02174419Phase 2/3
- Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo NodularisCompletedNCT02174432Phase 2/3
- Oral Abuse Potential Study of NalbuphineCompletedNCT04018664Phase 1